Antistaphylococcal Activity of CG400549, a New Experimental FabI Inhibitor, Compared with That of Other Agents

2007/09/18 by Tatiana Bogdanovich, Catherine Clark, Klaudia Kosowska-Shick +3
Medicine · Biochemistry, Genetics and Molecular Biology · #Antimicrobial Resistance in Staphylococcus #Bacterial biofilms and quorum sensing #Bacterial Identification and Susceptibility Testing

paper · doi:10.1128/aac.00550-07

Abstract

Among 203 strains of Staphylococcus aureus, the MICs of CG400549 were 0.06 to 1.0 microg/ml, with MIC(50) and MIC(90) values of 0.25 microg/ml each. All strains were susceptible to linezolid and quinupristin-dalfopristin (MICs, 0.25 to 2.0 microg/ml). The daptomycin MICs were 0.25 to 2.0 microg/ml for methicillin-susceptible and 0.25 to 4.0 microg/ml against methicillin-resistant strains (including vancomycin-intermediate strains). Single-passage selection testing showed low resistance frequencies with CG400549, but multistep analysis showed that CG400549 yielded resistant mutants after 14 to 17 days in all strains tested.

Citations

• The Enoyl‐[Acyl‐Carrier‐Protein] Reductase (FabI) of Escherichia coli, which Catalyzes a Key Regulatory Step in Fatty Acid Biosynthesis, Accepts NADH and NADPH as Cofactors and is Inhibited by Palmitoyl‐CoA

Related

• Synergy Test for Antibacterial Activity: Towards the Research for a Consensus between the Fractional Inhibitory Concentration (Checkboard Method) and the Increase in Fold Area (Disc Diffusion Method)
• Antimicrobial Peptides: A New Hope Against Antibiotic-Resistant Staphylococcus Species
• Bacterial Antibiotic Resistance: The Most Critical Pathogens
• Clovibactin and Staphylococcus aureus: a new weapon against resistant strains
• Anti-staphylococcal fatty acids: mode of action, bacterial resistance and implications for therapeutic application